CLINICAL
TRIALS
Studies Open to Accrual (April 2008)
ACUTE/RECENT
INFECTION
COZI
Study - "An Open-Label Randomized Clinical Trial to Evaluate
the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute
or Recent HIV-1 Infection in Zimbabwe and the United States."
ACTG A5217 - A Randomized Study of Treatment with Tenofovir DF, Emtricitabine, and Lopinavir/Ritonavir versus no Therapy in Newly Infected HIV-1 Infected Subjects to Determine Whether Potent Antiretroviral Therapy Alters the Virologic Setpoint"
EXPERIENCED
PATIENTS
ACTG
A5241 - "The Optimized Treatment that Includes
or Omits NRTIs (OPTIONS) Trial: A Randomized Strategy Study for HIV-1-Infected
Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen"
ACTG A5244- "A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification with a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia below 50 copies/mL in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens."
OPPORTUNISTIC
INFECTIONS/COMPLICATIONS/MISC
ACTG
A5212 - "A Double Blind Phase II Study of Multiple Doses
of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery
in Subjects on Potent Antiretroviral Therapy with Plasma HIV-1 RNA Levels
<=200 copies/mL."
ACTG
A5232 [Vaccine Response/HCV/HIV]
- "Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by
Identifying Determinants of Responsiveness: A Pilot Study"
ACTG A5235 [Neurocognitive Impairment] - "Phase II, Randomized, Placebo-Controlled, Double-Blind Study of Minocycline in the Treatment of HIV-Associated Cognitive Impairment"
ACTG A5240 (Opening Soon) [HPV/Women] - "A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females"
ACTG A5247 (Opening Soon) [Zostavax] - "A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX® in Human Immunodeficiency Virus (HIV)-1-Infected Adults on Potent Combination ART with Conserved Immune Function"
COMIRB
04-1101 - "Sex- and Disease-Dependent Nucleoside Analog Toxicity."
Return to HOME